Pepscan Therapeutics Closes a Research and License Agreement Aimed at the Development of Novel #Vaccines

Pepscan Therapeutics, the Dutch biotechnology firm focusing on protein mimicry technology, just announced that it has signed a Research and License Agreement with Crucell Holland B.V.

Crucell will make use of Pepscan’s proprietary technology and know-how in Crucell’s program for developing undisclosed novel vaccines to combat infectious diseases. Pepscan will receive research funding and could receive payments on the achievement by Crucell of research and clinical milestones, as well as royalties on sales of products resulting from the collaboration. Financial details of the agreement were not disclosed. Read the complete article

Crucell are sponsoring the 11th annual World Vaccine Congress Washington in April.  Download the brochure to find out more.